Hazel brings extensive oncology research experience across the pharmaceutical, biotech, academic, and charity sectors.

Before joining Enhanced Genomics, she held several key positions at AstraZeneca, including Executive Product Director of Clinical Data and Head of Business Planning and Operations in Oncology R&D. Additionally, she served as Head of Combination Therapies at Cancer Research UK. She also navigated the transition from biotech to pharma during the acquisition of Cambridge Antibody Technology by AstraZeneca.

Hazel excels in long-term strategic planning, encompassing both logistics and scientific deliverables and has been instrumental in steering the commercial transition of Enhanced Genomics from internal technology development to the external application of its platform.